# A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

> **NCT01834885** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** QVA149
- **DRUG:** fluticasone/salmeterol

## Key facts

- **NCT ID:** NCT01834885
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-12
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01834885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01834885, "A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01834885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*